Trial Profile
A Phase 3, Multicenter, Randomized, Open-label Study to Evaluate the Long-term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Atogepant (Primary) ; Antimigraines
- Indications Migraine
- Focus Adverse reactions; Registrational
- Sponsors AbbVie; Allergan
- 01 Aug 2023 Results published in the Cephalalgia
- 10 Dec 2022 Results of post hoc analysis of two studies(NCT03777059 and NCT03700320) assessing sustained initial responses of 50%, 75%, or 100% reduction in mean monthly migraine days (MMDs) over 12 and 52-weeks of atogepant treatment for episodic migraine presented at the 16th European headache federation COngress
- 12 Jun 2022 Results of post-hoc analysis of two studies (NCT03777059 & NCT03700320) assessing sustained response to atogepant in individuals with episodic migraine, presented at the 64th Annual Scientific Meeting of the American Headache Society.